NCT03028480View on ClinicalTrials.gov

Long Term Special Drug Use Investigation of Mepolizumab

CompletedOBSERVATIONAL

Enrollment

1,061

Participants

Timeline

Start Date

January 11, 2017

Primary Completion Date

November 22, 2023

Study Completion Date

November 22, 2023

Conditions

Asthma

Interventions

DRUG

NUCALA Injection

Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT03028480 - Long Term Special Drug Use Investigation of Mepolizumab | Biotech Hunter | Biotech Hunter